InFlectis BioScience raises €6 million in a Series A round
to perform clinical trial in humans.
Nantes, France – June 1st, 2016. InFlectis BioScience SAS, a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of protein misfolding diseases, today announced the completion of a Series A financing round amounting to €6 million. The financing was co-led by CM-CIC INNOVATION and REMIGES VENTURES with the participation of its historic shareholders, GO CAPITAL and PARTICIPATIONS BESANÇON. According to the financial terms of the agreement, the investors pay €4.5 million and have an investment option of an additional €1.5 million under certain pre-negotiated terms.